The synergistic effect of trastuzumab combined with different anti-HER3 antibodies, such as 1A 5 -3D4, and AKT inhibitors such as MK-2206, has been confirmed in several HER2-positive GC cell lines [32,33,34]. This evidence concerns the gene ERBB3 and gastric cancer.